EyeGate Pharmaceuticals, a late-stage biotech developing a treatment for eye inflammation, raised $10 million by offering 1.2 million shares and warrants at $8.50.
EyeGate postponed a $25 million NASDAQ IPO in late 2014 before listing on the OTCQB in February. In mid-July, the company had set terms to raise $13 million when its stock traded at $15 on the OTCQB, and on July 30 it filed an amendment adding warrants, exercisable at 125% of the offer price ($10.63). At $8.50, the company's fully diluted market value is $81 million.
EyeGate Pharmaceuticals plans to list on the Nasdaq under the symbol EYEG. Aegis Capital and Chardan Capital Markets acted as lead managers on the deal.
